Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of berberine in preparation of drugs for resisting chronic myeloid leukemia drug resistance

A chronic myeloid and leukemia technology, applied in the field of biomedicine, can solve the problem of unclear mechanism of action of berberine

Pending Publication Date: 2021-10-08
JINAN UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Berberine is increasingly important in leukemia research, however, the mechanism of action of berberine in the treatment of BCR-ABL1-independent drug resistance is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine in preparation of drugs for resisting chronic myeloid leukemia drug resistance
  • Application of berberine in preparation of drugs for resisting chronic myeloid leukemia drug resistance
  • Application of berberine in preparation of drugs for resisting chronic myeloid leukemia drug resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052]1. Experimental materials and methods

[0053] 1. Experimental reagents

[0054]

[0055]

[0056] 2. Primer sequence

[0057] Primers were designed and synthesized by Sangon Bioengineering (Shanghai) Co., Ltd., see Table 1.

[0058] Table 1. Primer sequences

[0059]

[0060] 3. Cell lines and human CML specimens

[0061] K562 cells (human chronic myeloid leukemia line) were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences; KCL22 cells (human chronic myeloid leukemia line) were kindly donated by Professor Muschen from the Children's Hospital of Los Angeles, USA; K562-IMR and KCL22-IMR (human chronic myeloid leukemia lines) Cell leukemia imatinib-resistant strain) was constructed by our laboratory; Plat-E cells were kindly donated by Professor Pan Jingxuan of Jinan University, and can also be purchased routinely; bone marrow samples of human CML patients came from the Second People's Hospital of Guangdong Province, and all experiments c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of berberine in preparation of drugs for resisting chronic myeloid leukemia drug resistance, and belongs to the field of biological medicines. According to the application of the berberine in preparation of the drugs for resisting chronic myeloid leukemia drug resistance, BCR-ABL1 non-dependent drug-resistant CML drug-resistant cell strains, such as K562-IMR and KCL22-IMR, are successfully constructed through a method of increasing the concentration of imatinib. The detection by an MTT method proves that the berberine can inhibit the proliferation of K562-IMR and KCL22-IMR cells; and in addition, the berberine can be used for remarkably inhibiting the clone formation capability of the K562-IMR cells and the KCL22-IMR cells. Meanwhile, the berberine has a remarkable inhibition effect on leukemia stem cells in a BCR-ABL1 induced leukemia model mouse. The berberine can inhibit the expression of a target protein JAK2, and also can inhibit the self-renewal of leukemia stem cells through the target protein JAK2, thereby overcoming the non-dependent drug resistance of BCR-ABL1 in CML.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of berberine in the preparation of anti-chronic myeloid leukemia drug resistance. Background technique [0002] Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease characterized by myeloid proliferation of hematopoietic stem cells in the blood system. Its typical genetic feature is the translocation to form the Philadelphia chromosome, and the resulting BCR-ABL1 fusion gene. Chronic myeloid leukemia is a hematological malignancy that endangers human health, accounting for about 15% of adult new-onset leukemia. The clinical course of CML can be divided into chronic phase (CP), accelerated phase (AP) and explosive phase (BP) [1] . Prior to the introduction of TKIs (tyrosine kinase inhibitors), the mainstay of treatment was interferon alpha (IFN-alpha) and stem cell transplantation [2] . Responses to IFN-α are seldom durable and the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K36/718A61K45/06A61K31/7088A61K31/506A61P35/02
CPCA61K31/4375A61K36/718A61K45/06A61K31/7088A61K31/506A61P35/02A61K2300/00
Inventor 费嘉黄桂萍
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com